UFP Technologies Inc (UFPT) stock analysis
Close on Nov 12, 2026Market cap $2.37BP/E 31.2Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Mixed14 of 30 checks passed
UFP Technologies passes 14 of the 30 checks behind our score; 6 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 3/6
- Past performance
- 6/6
- Financial health
- 5/6
- Dividend
- 0/6
What stands out
Return on equity over 15%
Return on equity was 17.2% over the last twelve months and averaged 16.3% over five years.
Return on capital over 10%
Return on invested capital was 15.0%, above the 10% that usually covers the cost of capital.
Low debt
Debt is 19.8% of shareholders' equity, under the 40% we consider low.
Earnings grew over 5 years
Net income grew 38.6% a year on average over the last five fiscal years.
What to watch
Margin of safety under 20%
The price is 21.9% above fair value, so there is no margin of safety.
Trading above fair value
The share price of $314.05 is above our fair value estimate of $257.61.
Earnings growth not accelerating
Net income grew 14.0% over the last twelve months, against a 5-year average of 38.6% a year.
P/E above its 5-year median
UFP Technologies's P/E of 32.0 is above its own 5-year median of 30.7.
Valuation0/6
P/E above its 5-year median
UFP Technologies's P/E of 32.0 is above its own 5-year median of 30.7.
P/E above the industry
UFP Technologies's P/E of 32.0 is above the Surgical, Medical, and Dental Instruments and Supplies median of 27.7.
EV/EBITDA above its 5-year median
UFP Technologies's EV/EBITDA of 24.9 is above its 5-year median of 20.1.
P/B above the industry
UFP Technologies's price-to-book of 5.01 is above the Surgical, Medical, and Dental Instruments and Supplies median of 3.22.
Trading above fair value
The share price of $314.05 is above our fair value estimate of $257.61.
Margin of safety under 20%
The price is 21.9% above fair value, so there is no margin of safety.
Growth3/6
Revenue growing 10%+ a year
Revenue grew 19.4% a year over the last three fiscal years.
EPS growing 10%+ a year
Diluted EPS grew 17.1% a year over the last three fiscal years.
Earnings growth not accelerating
Net income grew 14.0% over the last twelve months, against a 5-year average of 38.6% a year.
Growing slower than the industry
Revenue grew 8.6% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 11.0%.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin improving
Gross margin was 28.9% over the last twelve months, against 28.5% a year earlier.
Past performance6/6
Return on equity over 15%
Return on equity was 17.2% over the last twelve months and averaged 16.3% over five years.
Return on capital over 10%
Return on invested capital was 15.0%, above the 10% that usually covers the cost of capital.
Return on equity above the industry
UFP Technologies's return on equity of 17.2% is above the Surgical, Medical, and Dental Instruments and Supplies median of -31.3%.
Earnings grew over 5 years
Net income grew 38.6% a year on average over the last five fiscal years.
Net margin above its 5-year average
Net margin was 11.8% over the last twelve months, against a 5-year average of 10.8%.
Net margin above the industry
UFP Technologies's net margin of 11.8% is above the Surgical, Medical, and Dental Instruments and Supplies median of -14.1%.
Financial health5/6
Low debt
Debt is 19.8% of shareholders' equity, under the 40% we consider low.
Debt rising against equity
Debt to equity rose from 0.0% five years ago to 19.8%.
Debt covered by cash flow
Operating cash flow over the last twelve months equals 77.3% of total debt.
Interest well covered
Operating income covers interest expense 14.6 times.
Short-term assets cover short-term debts
Current assets are 2.98 times current liabilities.
Low bankruptcy risk
The Altman Z-score is 10.01; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
UFP Technologies has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itOur estimate per share
$257.61
The share price is 22% above this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/E | 29.2× | 30.7× | 27.7× | $286.23 | 47% |
| EV/EBITDA | 18.4× | 20.1× | 16.7× | $228.84 | 41% |
| P/B | 3.9× | 4.6× | 3.2× | $243.83 | 12% |
| Earnings powerleft out, too far from the others | 10.1% cost of equity | – | – | $76.29 | – |
| Fair value | $257.61 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 30.7
- Surgical, Medical, and Dental Instruments and Supplies median 27.7
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $33.61M
- Value traded per 1% price move
- $21.10M
Downside
Medium risk
- Typical loss in a bad month
- 20.6%
- Volatility (annualized)
- 51%
- Sharpe ratio, 1 year
- 0.58
- Beta to the S&P 500 (5Y)
- 1.05
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +19.5% | +19.4% | +27.4% | +15.8% | |
| Gross profit | +16.2% | +23.6% | +30.7% | +16.4% | |
| Operating income | +14.1% | +18.6% | +40.7% | +22.9% | |
| Net income | +15.8% | +17.8% | +38.6% | +24.6% | |
| EPS, diluted | +15.4% | +17.1% | +37.7% | +23.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 7.4% | 7.9% | 17.8% | |
| Return on assets | 6.4% | 6.8% | 10.6% | |
| Current ratio | 7.31 | 4.75 | 2.68 | |
| Debt to equity | – | 0.00 | 0.32 | |
| Net debt to EBITDA | – | -0.97× | 1.03× | |
| Interest coverage | 177.3× | 201.6× | 9.4× | |
| Inventory turnover | 7.9× | 7.3× | 5.0× | |
| Capex to revenue | 4.9% | 2.4% | – | |
| Diluted shares | 7M | 8M | 8M |
Cash use needs five years of cash flow figures
UFP Technologies does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 11.3% | 0.94× | 1.67× | 17.8% |
| FY2024 | 11.7% | 0.98× | 1.64× | 18.8% |
| FY2023 | 11.2% | 1.02× | 1.49× | 17.2% |
| FY2022 | 11.8% | 0.99× | 1.65× | 19.3% |
| FY2021 | 7.7% | 0.77× | 1.45× | 8.6% |
| FY2020 | 7.5% | 0.92× | 1.16× | 7.9% |
| FY2019 | 10.0% | 1.05× | 1.25× | 13.1% |
| FY2018 | 7.5% | 1.16× | 1.24× | 10.8% |
| FY2017 | 6.2% | 1.11× | 1.12× | 7.8% |
| FY2016 | 5.5% | 1.18× | 1.14× | 7.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$68.31M
- Cash generatingOperating cash flow above zero$91.91M
- Return on assets improvedROA up on the prior year14.6% → 10.9%
- Earnings backed by cashOperating cash flow above net income$91.91M vs $68.31M
- Less leverageLong-term debt to assets fell28.1% → 18.8%
- Better liquidityCurrent ratio rose2.56 → 2.68
- No dilutionShare count did not rise8M → 8M
- Gross margin improvedGross margin up on the prior year29.08% → 28.27%
- More efficientAsset turnover rose1.25 → 0.96
See a number that looks wrong?